Aristippos Gennadios compensation by year
Catalent Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $485,769 | $600,000 |
| Bonus | $0 | $0 |
| Stock awards | $850,275 | $2,700,277 |
| Option awards | $150,008 | $300,017 |
| Non-equity incentive | $572,240 | $135,000 |
| Pension and deferred compensation | $0 | $0 |
| All other | $67,212 | $64,263 |
| Total | $2,125,504 | $3,799,557 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Catalent, Inc. DEF 14A filed December 15, 2023, accession 0001193125-23-295996, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Catalent, Inc. filed document, accession 0001193125-23-295996. Every figure is read from that document and cited to the page and table it appears in. Filed December 15, 2023.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 1,372,127 | $1,100,000 | — |
| RSU | 1,575,572 | $1,100,000 | — |
| RSU | 1,100,000 | $881,843 | — |
| RSU | 301,222 | $301,222 | — |
| PSU | 6,155 | $4,934 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Catalent, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
6 Form 4 lines since the FY2023 proxy (filed December 15, 2023)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-12-18 | Grant or award | — | 21,562 | $0.00 | 21,562 |
| 2024-12-18 | Disposition to the issuer | — | 113,724 | — | 0 |
| 2024-12-18 | Disposition to the issuer | — | 21,562 | — | 0 |
| 2024-08-02 | Sale | — | 1,169 | $59.55 | 113,724 |
| 2024-07-29 | Sale | — | 349 | $58.70 | 114,893 |
| 2024-07-26 | Grant or award | — | 18,746 | $0.00 | 115,242 |
The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Catalent’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Alessandro Maselli | President and Chief Executive Officer | $6,583,672 |
| John Chiminski | Former Executive Chair | $4,807,767 |
| Manja Boerman | Former President, Division Head for Biomodalities | $3,979,888 |
| Aristippos Gennadios · this page | Group President, Pharma and Consumer Health | $3,799,557 |
| Thomas Castellano | Former Senior Vice President and Chief Financial Officer | $2,729,983 |
| Steven Fasman | Former Executive Vice President & Chief Administrative Officer | $2,310,299 |
| Ricky Hopson | President, Division Head for Clinical Development & Supply and Former Interim Chief Financial Officer | $972,307 |
The full Catalent compensation record
free company briefThis page is one person within Catalent's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Catalent proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Catalent's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.